Reltecimod FDA Approval Status
Last updated by Judith Stewart, BPharm on Jan 6, 2021.
FDA Approved: No
Generic name: reltecimod
Company: Atox Bio
Treatment for: Organ Dysfunction or Failure in Patients with Necrotizing Soft Tissue Infection
Reltecimod is an immunomodulator peptide in development for the treatment of suspected organ dysfunction or failure in patients with necrotizing soft tissue infection (NSTI).
Development Timeline for reltecimod
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.